Advanced

Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy

Riihijarvi, Sari; Taskinen, Minna; Jerkeman, Mats LU and Leppa, Sirpa (2011) In European Journal of Haematology 86(2). p.124-128
Abstract
Male gender is an adverse prognostic factor in Hodgkin's lymphoma, but no such association has yet been established in non-Hodgkin lymphomas. Here, we have evaluated whether gender has prognostic impact on the survival of patients with B-cell non-Hodgkin lymphoma in the postrituximab era of lymphoma therapies. The study populations consisted of 217 diffuse large B-cell lymphoma (DLBCL) and 110 follicular lymphoma (FL) patients treated with immunochemotherapy. Hundred and sixty chemotherapy-treated DLBCL patients served as a control group. According to Kaplan-Meier analyses, female patients had a significantly better progression-free survival than men both in DLBCL (4 yr PFS 75% vs. 60%; P = 0.013) and in FL (4 yr PFS 68% vs. 52%, P =... (More)
Male gender is an adverse prognostic factor in Hodgkin's lymphoma, but no such association has yet been established in non-Hodgkin lymphomas. Here, we have evaluated whether gender has prognostic impact on the survival of patients with B-cell non-Hodgkin lymphoma in the postrituximab era of lymphoma therapies. The study populations consisted of 217 diffuse large B-cell lymphoma (DLBCL) and 110 follicular lymphoma (FL) patients treated with immunochemotherapy. Hundred and sixty chemotherapy-treated DLBCL patients served as a control group. According to Kaplan-Meier analyses, female patients had a significantly better progression-free survival than men both in DLBCL (4 yr PFS 75% vs. 60%; P = 0.013) and in FL (4 yr PFS 68% vs. 52%, P = 0.036) patients treated with immunochemotherapy. In chemotherapy-treated DLBCL patients, no difference in survival between the genders was found. The results support the idea that women seem to respond better to rituximab. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
B-cell non-Hodgkin lymphoma, prognostic factors, gender, immunochemotherapy
in
European Journal of Haematology
volume
86
issue
2
pages
124 - 128
publisher
Wiley-Blackwell
external identifiers
  • wos:000286206700004
  • scopus:78651465901
  • pmid:20942853
ISSN
1600-0609
DOI
10.1111/j.1600-0609.2010.01541.x
language
English
LU publication?
yes
id
b5898530-e12f-4abc-8b63-7635ce7d374f (old id 1790908)
date added to LUP
2011-03-02 13:28:32
date last changed
2017-10-01 03:17:21
@article{b5898530-e12f-4abc-8b63-7635ce7d374f,
  abstract     = {Male gender is an adverse prognostic factor in Hodgkin's lymphoma, but no such association has yet been established in non-Hodgkin lymphomas. Here, we have evaluated whether gender has prognostic impact on the survival of patients with B-cell non-Hodgkin lymphoma in the postrituximab era of lymphoma therapies. The study populations consisted of 217 diffuse large B-cell lymphoma (DLBCL) and 110 follicular lymphoma (FL) patients treated with immunochemotherapy. Hundred and sixty chemotherapy-treated DLBCL patients served as a control group. According to Kaplan-Meier analyses, female patients had a significantly better progression-free survival than men both in DLBCL (4 yr PFS 75% vs. 60%; P = 0.013) and in FL (4 yr PFS 68% vs. 52%, P = 0.036) patients treated with immunochemotherapy. In chemotherapy-treated DLBCL patients, no difference in survival between the genders was found. The results support the idea that women seem to respond better to rituximab.},
  author       = {Riihijarvi, Sari and Taskinen, Minna and Jerkeman, Mats and Leppa, Sirpa},
  issn         = {1600-0609},
  keyword      = {B-cell non-Hodgkin lymphoma,prognostic factors,gender,immunochemotherapy},
  language     = {eng},
  number       = {2},
  pages        = {124--128},
  publisher    = {Wiley-Blackwell},
  series       = {European Journal of Haematology},
  title        = {Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy},
  url          = {http://dx.doi.org/10.1111/j.1600-0609.2010.01541.x},
  volume       = {86},
  year         = {2011},
}